These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18761548)

  • 1. Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain-Barré syndrome.
    Rhee DY; Park GH; Chang SE; Lee MW; Choi JH; Moon KC; Koh JK
    J Eur Acad Dermatol Venereol; 2009 May; 23(5):602-4. PubMed ID: 18761548
    [No Abstract]   [Full Text] [Related]  

  • 2. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
    Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
    No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease.
    Iannaccone S; Sferrazza B; Quattrini A; Smirne S; Ferini-Strambi L
    Neurology; 1999 Sep; 53(5):1154-5. PubMed ID: 10496291
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
    Shiraishi T; Yamamoto T
    Pediatr Dermatol; 2013; 30(3):e30-1. PubMed ID: 22304420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pompholyx after IV immunoglobulin therapy for neurologic disease.
    Ikeda K; Iwasaki Y; Ichikawa Y; Kinoshita M
    Neurology; 2000 May; 54(9):1879. PubMed ID: 10802813
    [No Abstract]   [Full Text] [Related]  

  • 6. Pompholyx induced by intravenous immunoglobulin therapy.
    Llombart M; García-Abujeta JL; Sánchez-Pérez RM; Hernando de Larramendi C
    J Investig Allergol Clin Immunol; 2007; 17(4):277-8. PubMed ID: 17694704
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
    Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
    Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guillain-Barré syndrome associated with scrub typhus.
    Lee SH; Jung SI; Park KH; Choi SM; Park MS; Kim BC; Kim MK; Cho KH
    Scand J Infect Dis; 2007; 39(9):826-8. PubMed ID: 17701724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guillain-Barré syndrome. What should be done, when the treatment appears to fail?].
    Tellería-Díaz A
    Rev Neurol; 2003 Oct 16-31; 37(8):798-800. PubMed ID: 14593645
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in guillain-barre syndrome.
    Doss-Esper CE; Singhal AB; Smith MS; Henderson GV
    J Neuroimaging; 2005 Apr; 15(2):188-92. PubMed ID: 15746232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV.
    Makela P; Howe L; Glover S; Ferguson I; Pinto A; Gompels M
    J Infect; 2002 Jan; 44(1):47-9. PubMed ID: 11972420
    [No Abstract]   [Full Text] [Related]  

  • 12. [Guillain-Barré syndrome].
    Kusunoki S
    Nihon Rinsho; 2005 May; 63 Suppl 5():427-31. PubMed ID: 15954387
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
    Alshekhlee A; Hussain Z; Sultan B; Katirji B
    J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of Guillain-Barre syndrome with pregnancy.
    Vijayaraghavan J; Vasudevan D; Sadique N; Rajeswari KS; Pondurangi M; Jayshree
    J Indian Med Assoc; 2006 May; 104(5):269-70. PubMed ID: 17058576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune supplementation and immune modulation with intravenous immunoglobulin.
    Mazer BD; Al-Tamemi S; Yu JW; Hamid Q
    J Allergy Clin Immunol; 2005 Oct; 116(4):941-4. PubMed ID: 16210080
    [No Abstract]   [Full Text] [Related]  

  • 16. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case.
    Brazzelli V; Grassi S; Savasta S; Ruffinazzi G; Carugno A; Barbaccia V; Marseglia GL; Borroni G
    Int J Immunopathol Pharmacol; 2014; 27(1):127-30. PubMed ID: 24674688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Appropriate method of apheresis in Guillain-Barré syndrome].
    Ito H; Saito T; Sakai F
    Rinsho Shinkeigaku; 1999 Nov; 39(11):1168-70. PubMed ID: 10689945
    [No Abstract]   [Full Text] [Related]  

  • 18. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
    Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
    J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose intravenous immunoglobulin therapy in dysimmune neuropathies.
    Nobile-Orazio E; Bersano A
    Neurol Sci; 2002 Apr; 23 Suppl 1():S25-32. PubMed ID: 12032584
    [No Abstract]   [Full Text] [Related]  

  • 20. Human immunoglobulin and the Guillain-Barre syndrome: new indication. An alternative to plasmapheresis.
    Prescrire Int; 2000 Oct; 9(49):142-3. PubMed ID: 11603414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.